Home » Topics » Regulatory » EMA

EMA
RSS

EMA accepts for review lurasidone MAA

Oct. 25, 2012

Xalkori granted conditional approval in Europe

Oct. 25, 2012

CHMP recommends approval of Krystexxa

Oct. 23, 2012

Mirabegron recommended for European approval

Oct. 22, 2012

EMA's CHMP recommends approval of Amyvid

Oct. 22, 2012

CHMP recommends Abbott's Humira in pediatric Crohn's disease

Oct. 22, 2012

Tresiba and Ryzodeg receive positive CHMP opinions

Oct. 22, 2012

CHMP recommends Bayer's anticoagulant for additional use

Oct. 22, 2012

EMA committee issues opinion on Qsiva

Oct. 19, 2012

EMA accepts masitinib MAA for review

Oct. 8, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...